Skip to main content

Table 2 Second-line chemotherapy which eligible patients received and tumor response evaluated RECIST ver1.1

From: Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Regimen BBP group (%) Non-BBP group (%)
Oxaliplatin-based
 FOLFOX 0 (0) 1 (4.0)
 FOLFOX+BEV 7 (18.9) 0 (0)
Irinotecan-based
 FOLFIRI 0 (0) 4 (16.0)
 FOLFIRI+CET/PANI 0 (0) 8 (32.0)
 Irinotecan 0 (0) 4 (16.0)
 Irinotecan+CET/PANI 0 (0) 4 (16.0)
 FOLFIRI+BEV 26 (70.3) 0 (0)
 IRIS+BEV 2 (5.4) 0 (0)
 XELIRI+BEV 1 (2.7) 0 (0)
 FOLFIRI+RAM 1 (2.7) 0 (0)
EGFR antibody alone
 CET/PANI 0 (0) 4 (16.0)
Tumor response
Best response BBP groupa (%)
N = 35 		Non-BBP groupa (%)
N = 22
 Complete response 0 (0) 0 (0)
 Partial response 3 (8.6) 2 (9.1)
 Stable disease 15 (42.9) 6 (27.3)
 Progressive disease 14 (40.0) 12 (54.5)
 Not evaluated 3 (8.6) 2 (9.1)
 Objective response rate 3 (8.6) 2 (9.1)
 Disease control rate 18 (51.4) 8 (36.4)
  1. Abbreviations: BBP Bevacizumab continuation beyond progression, BEV Bevacizumab, FOLFOX 5-FU and leucovorin, oxaliplatin, FOLFIRI 5-FU and leucovorin, irinotecan, IRIS Irinotecan and S-1, XELIRI capecitabine and irinotecan, RAM Ramucirumab, CET Cetuximab, PANI Panitumumab, EGFP Epidermal growth factor receptor
  2. aPatients who had measurable lesions
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us